EGFR and familial pancreatic carcinoma: For example, Oberg et al. showed the enhancement of γδ T cell cytotoxicity by an anti-Her2/anti-Vγ9 antibody against pancreatic cancer cells [26], Ganesan et al. described the impact of an anti-CD123/anti-Vγ9 antibody against acute myeloid leukemia cells [27], King et al. introduced an anti-EGFR/anti-Vδ2 antibody against Epidermal Growth Factor Receptor (EGFR)-expressing tumor cells [28], and Yang et al. used Vγ2Vδ2 T cells as effector cells against programmed cell death-ligand 1 (PD-L1)-expressing target cells through administration of an anti-PD-L1/anti-Vγ2 antibody [29].